Nonstandard drugs and feasible new interventions for autoimmune hepatitis: Part II

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 5, 2012, Pages 351-363

  Czaja, Albert J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autoimmune hepatitis; Cellular manipulations; Gene silencing; Molecular interventions

Indexed keywords

ABATACEPT; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; VELTUZUMAB;

ARTICLE; AUTOIMMUNE HEPATITIS; B CELL LYMPHOMA; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DISEASE ACTIVITY; DRUG EFFICACY; GENE SILENCING; GENETIC POLYMORPHISM; HOMEOSTASIS; HUMAN; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PLASMA CELL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; RNA, SMALL INTERFERING; T-LYMPHOCYTES, REGULATORY;

EID: 84867739910     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812803250980     Document Type: Article

References (210)

1. Czaja, A.J. Current and future treatments of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol., 2009, 3 (3), 269-291.
2. Czaja, A.J. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig. Dis. Sci., 2010, 55 (10), 2712-2726.
3. Czaja, A.J.; Manns, M.P. Advances in the diagnosis, pathogenesis and management of autoimmune hepatitis. Gastroenterology, 2010, 139 (1), 58-72.
4. Czaja, A.J. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr. Pharm. Des., 2011, 17 (29), 3120-3140.
5. Ribas, A. Anti-CTLA4 Antibody Clinical Trials in Melanoma. Update Cancer Ther., 2007, 2 (3), 133-139.
6. Tran, L.; Baars, J.W.; Aarden, L.; Beijnen, J.H.; Huitema, A.D. Pharmacokinetics of rituximab in patients with CD20 positive Bcell malignancies. Hum. Antibodies, 2010, 19 (1), 7-13.
7. Leandro, M.J.; Becerra-Fernandez, E. B-cell therapies in established rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol., 2011, 25 (4), 535-548.
8. Kremer, J.M.; Russell, A.S.; Emery, P.; Abud-Mendoza, C.; Szechinski, J.; Westhovens, R.; Li, T.; Zhou, X.; Becker, J.C.; Aranda, R.; Peterfy, C.; Genant, H.K. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann. Rheum. Dis., 2011, 70 (10), 1826-1830.
9. Jani, M.; Hyrich, K.L. Abatacept in the long-term treatment of rheumatoid arthritis. Expert Rev. Clin. Immunol., 2012, 8 (3), 231-234.
10. McHutchison, J.G.; Giannelli, G.; Nyberg, L.; Blatt, L.M.; Waite, K.; Mischkot, P.; Pianko, S.; Conrad, A.; Grint, P. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection. J. Interferon Cytokine Res., 1999, 19 (11), 1265-1270.
11. Carreno, V.; Zeuzem, S.; Hopf, U.; Marcellin, P.; Cooksley, W.G.; Fevery, J.; Diago, M.; Reddy, R.; Peters, M.; Rittweger, K.; Rakhit, A.; Pardo, M. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J. Hepatol., 2000, 32 (2), 317-324.
12. Fedorak, R.N.; Gangl, A.; Elson, C.O.; Rutgeerts, P.; Schreiber, S.; Wild, G.; Hanauer, S.B.; Kilian, A.; Cohard, M.; LeBeaut, A.; Feagan, B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology, 2000, 119 (6), 1473-1482.
13. Nelson, D.R.; Lauwers, G.Y.; Lau, J.Y.; Davis, G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology, 2000, 118 (4), 655-660.
14. Li, M.C.; He, S.H. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol., 2004, 10 (5), 620-625.
15. Blumenfeld, H.J.; Tohn, R.; Haeryfar, S.M.; Liu, Y.; Savage, P.B.; Delovitch, T.L. Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. Clin. Exp. Immunol., 2011, 166 (1), 121-133.
16. Longhi, M.S.; Hussain, M.J.; Kwok, W.W.; Mieli-Vergani, G.; Ma, Y.; Vergani, D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology, 2011, 53 (2), 536-547.
17. Chatenoud, L. Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Curr. Opin. Organ Transpl., 2009, 14 (4), 351-356.
18. Czaja, A.J. Emerging treatments for autoimmune hepatitis. Curr. Drug Targets Inflamm. Allergy, 2002, 1 (4), 317-326.
19. Czaja, A.J. Progress in the diagnosis and treatment of autoimmune hepatitis. Minerva Med., 2008, 99 (6), 549-568.
20. Smith, C.A.; Williams, G.T.; Kingston, R.; Jenkinson, E.J.; Owen, J.J. Antibodies to CD3/T-cell receptor complex induce death by apoptosis in immature T cells in thymic cultures. Nature, 1989, 337 (6203), 181-184.
21. Chatenoud, L.; Bluestone, J.A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol., 2007, 7 (8), 622-632.
22. Ochi, H.; Abraham, M.; Ishikawa, H.; Frenkel, D.; Yang, K.; Basso, A.; Wu, H.; Chen, M.L.; Gandhi, R.; Miller, A.; Maron, R.; Weiner, H.L. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J. Neurol. Sci., 2008, 274 (1-2), 9-12.
23. Chatenoud, L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found. Symp., 2003, 252, 279-286; discussion 286-290.
24. Perruche, S.; Zhang, P.; Liu, Y.; Saas, P.; Bluestone, J.A.; Chen, W. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells. Nat. Med., 2008, 14 (5), 528-535.
25. Kohm, A.P.; Turley, D.M.; Miller, S.D. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease. Int. Rev. Immunol., 2005, 24 (5-6), 361-392.
26. Chatenoud, L. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr. Opin. Immunol., 2005, 17 (6), 632-637.
27. Chatenoud, L. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic. Handb. Exp. Pharmacol., 2008, (181), 221-236.
28. Ferran, C.; Sheehan, K.; Dy, M.; Schreiber, R.; Merite, S.; Landais, P.; Noel, L.H.; Grau, G.; Bluestone, J.; Bach, J.F.; et al. Cytokinerelated syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol., 1990, 20 (3), 509-515.
29. Chatenoud, L.; Thervet, E.; Primo, J.; Bach, J.F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl. Acad. Sci. U S A, 1994, 91 (1), 123-127.
30. Bresson, D.; Togher, L.; Rodrigo, E.; Chen, Y.; Bluestone, J.A.; Herold, K.C.; von Herrath, M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest., 2006, 116 (5), 1371-1381.
31. von Herrath, M.G.; Coon, B.; Wolfe, T.; Chatenoud, L. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance. J. Immunol., 2002, 168 (2), 933-941.
32. Ishikawa, H.; Ochi, H.; Chen, M.L.; Frenkel, D.; Maron, R.; Weiner, H.L. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes, 2007, 56 (8), 2103-2109.
33. Herold, K.C.; Hagopian, W.; Auger, J.A.; Poumian-Ruiz, E.; Taylor, L.; Donaldson, D.; Gitelman, S.E.; Harlan, D.M.; Xu, D.; Zivin, R.A.; Bluestone, J.A. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med., 2002, 346 (22), 1692-1698.
34. Herold, K.C.; Gitelman, S.E.; Masharani, U.; Hagopian, W.; Bisikirska, B.; Donaldson, D.; Rother, K.; Diamond, B.; Harlan, D.M.; Bluestone, J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in Cpeptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes, 2005, 54 (6), 1763-1769.
35. Kaufman, A.; Herold, K.C. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab. Res. Rev., 2009, 25 (4), 302-306.
36. Keymeulen, B.; Vandemeulebroucke, E.; Ziegler, A.G.; Mathieu, C.; Kaufman, L.; Hale, G.; Gorus, F.; Goldman, M.; Walter, M.; Candon, S.; Schandene, L.; Crenier, L.; De Block, C.; Seigneurin, J.M.; De Pauw, P.; Pierard, D.; Weets, I.; Rebello, P.; Bird, P.; Berrie, E.; Frewin, M.; Waldmann, H.; Bach, J.F.; Pipeleers, D.; Chatenoud, L. Insulin needs after CD3-antibody therapy in newonset type 1 diabetes. N. Engl. J. Med., 2005, 352 (25), 2598-2608.
37. Jaeckel, E. Animal models of autoimmune hepatitis. Semin. Liver Dis., 2002, 22 (4), 325-338.
38. Lapierre, P.; Djilali-Saiah, I.; Vitozzi, S.; Alvarez, F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. Hepatology, 2004, 39 (4), 1066-1074.
39. Holdener, M.; Hintermann, E.; Bayer, M.; Rhode, A.; Rodrigo, E.; Hintereder, G.; Johnson, E.F.; Gonzalez, F.J.; Pfeilschifter, J.; Manns, M.P.; Herrath, M.G.; Christen, U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J. Exp. Med., 2008, 205 (6), 1409-1422.
40. Christen, U.; Hintermann, E.; Jaeckel, E. New animal models for autoimmune hepatitis. Semin. Liver Dis., 2009, 29 (3), 262-272.
41. Czaja, A.J. Animal models of autoimmune hepatitis. Expert Rev. Gastroenterol. Hepatol., 2010, 4 (4), 429-443.
42. van Meerten, T.; Hagenbeek, A. CD20-targeted therapy: the next generation of antibodies. Semin. Hematol., 2010, 47 (2), 199-210.
43. Weiner, G.J. Rituximab: mechanism of action. Semin. Hematol., 2010, 47 (2), 115-123.
44. Borker, A.; Choudhary, N. Rituximab. Indian Pediatr., 2011, 48 (8), 627-632.
45. Amoroso, A.; Hafsi, S.; Militello, L.; Russo, A.E.; Soua, Z.; Mazzarino, M.C.; Stivala, F.; Libra, M. Understanding rituximab function and resistance: implications for tailored therapy. Front. Biosci., 2011, 16, 770-782.
46. Winiarska, M.; Glodkowska-Mrowka, E.; Bil, J.; Golab, J. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front. Biosci., 2011, 16, 277-306.
47. Goldenberg, D.M.; Morschhauser, F.; Wegener, W.A. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk. Lymphoma, 2010, 51 (5), 747-755.
48. Ferri, C.; Cacoub, P.; Mazzaro, C.; Roccatello, D.; Scaini, P.; Sebastiani, M.; Tavoni, A.; Zignego, A.L.; De Vita, S. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun. Rev., 2011, 11 (1), 48-55.
49. Catanoso, M.; Pipitone, N.; Magnani, L.; Boiardi, L.; Salvarani, C. New indications for biological therapies. Intern. Emerg. Med., 2011, 6 (Suppl 1), 1-9.
50. Murdaca, G.; Colombo, B.M.; Puppo, F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun. Rev., 2011, 11 (1), 56-60.
51. Bosello, S.; De Luca, G.; Tolusso, B.; Lama, G.; Angelucci, C.; Sica, G.; Ferraccioli, G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun. Rev., 2011, 10 (10), 624-630.
52. Kumar, D.; Roubey, R.A. Use of rituximab in the antiphospholipid syndrome. Curr. Rheumatol. Rep., 2010, 12 (1), 40-44.
53. Cross, A.H.; Waubant, E. MS and the B cell controversy. Biochim. Biophys. Acta, 2011, 1812 (2), 231-238.
54. Barun, B.; Bar-Or, A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin. Immunol., 2012, 142 (1), 31-37.
55. Santos, E.S.; Arosemena, L.R.; Raez, L.E.; O'Brien, C.; Regev, A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int., 2006, 26 (5), 625-629.
56. Sanford, M.; McCormack, P.L. Ofatumumab. Drugs, 2010, 70 (8), 1013-1019.
57. Osterborg, A. Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opin. Biol. Ther., 2010, 10 (3), 439-449.
58. O'Brien, S.; Osterborg, A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin. Lymphoma Myeloma Leuk., 2010, 10 (5), 361-368.
59. Nightingale, G. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. Ann. Pharmacother., 2011, 45 (10), 1248-1255.
60. Veliz, M.; Pinilla-Ibarz, J. Role of ofatumumab in treatment of chronic lymphocytic leukemia. J. Blood Med., 2011, 2, 71-77.
61. Levesque, M.C. Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin. Exp. Immunol., 2009, 157 (2), 198-208.
62. Czaja, A.J. Autoantibodies. Baillieres Clin. Gastroenterol., 1995, 9 (4), 723-744.
63. Czaja, A.J.; Norman, G.L. Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol., 2003, 37 (4), 315-329.
64. Czaja, A.J. Autoantibodies in autoimmune liver disease. Adv. Clin. Chem., 2005, 40, 127-164.
65. McFarlane, I.G. Pathogenesis of autoimmune hepatitis. Biomed. Pharmacother., 1999, 53 (5-6), 255-263.
66. Czaja, A.J. Understanding the pathogenesis of autoimmune hepatitis. Am. J. Gastroenterol., 2001, 96 (4), 1224-1231.
67. Czaja, A.J. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev. Gastroenterol. Hepatol., 2007, 1 (1), 113-128.
68. Czaja, A.J. Autoimmune hepatitis. Evolving concepts and treatment strategies. Dig. Dis. Sci., 1995, 40 (2), 435-456.
69. Page, A.R.; Condie, R.M.; Good, R.A. Suppression of Plasma Cell Hepatitis with 6-Mercaptopurine. Am. J. Med., 1964, 36, 200-213.
70. Czaja, A.J.; Carpenter, H.A. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int., 2003, 23 (2), 116-123.
71. Verma, S.; Gunuwan, B.; Mendler, M.; Govindrajan, S.; Redeker, A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am. J. Gastroenterol., 2004, 99 (8), 1510-1516.
72. Takahashi, T.; Miura, T.; Nakamura, J.; Yamada, S.; Yanagi, M.; Matsuda, Y.; Usuda, H.; Emura, I.; Tsuneyama, K.; He, X.S.; Gershwin, M.E. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology, 2012, 55 (3), 846-855.
73. Lohr, H.; Manns, M.; Kyriatsoulis, A.; Lohse, A.W.; Trautwein, C.; Meyer zum Buschenfelde, K.H.; Fleischer, B. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin. Exp. Immunol., 1991, 84 (2), 297-302.
74. van der Kolk, L.E.; Baars, J.W.; Prins, M.H.; van Oers, M.H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood, 2002, 100 (6), 2257-2259.
75. Renaudineau, Y.; Devauchelle-Pensec, V.; Hanrotel, C.; Pers, J.O.; Saraux, A.; Youinou, P. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine, 2009, 76 (5), 458-463.
76. Dalakas, M.C. B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol., 2008, 4 (10), 557-567.
77. Meier, U.C.; Giovannoni, G.; Tzartos, J.S.; Khan, G. Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system? Clin. Exp. Immunol., 2012, 167 (1), 1-6.
78. Stasi, R. Rituximab in autoimmune hematologic diseases: not just a matter of B cells. Semin. Hematol., 2010, 47 (2), 170-179.
79. Cooper, N.; Arnold, D.M. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol., 2010, 149 (1), 3-13.
80. Liossis, S.N.; Sfikakis, P.P. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells. Clin. Immunol., 2008, 127 (3), 280-285.
81. Dorner, T.; Kinnman, N.; Tak, P.P. Targeting B cells in immunemediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol. Ther., 2010, 125 (3), 464-475.
82. Tedder, T.F. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol., 2009, 5 (10), 572-577.
83. Rezvani, A.R.; Maloney, D.G. Rituximab resistance. Best Pract. Res. Clin. Haematol., 2011, 24 (2), 203-216.
84. Wolach, O.; Shpilberg, O.; Lahav, M. Neutropenia after rituximab treatment: new insights on a late complication. Curr. Opin. Hematol., 2012, 19 (1), 32-38.
85. Mastroianni, C.M.; Lichtner, M.; Citton, R.; Del Borgo, C.; Rago, A.; Martini, H.; Cimino, G.; Vullo, V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J. Gastroenterol., 2011, 17 (34), 3881-3887.
86. Uettwiller, F.; Rigal, E.; Hoarau, C. Infections associated with monoclonal antibody and fusion protein therapy in humans. MAbs, 2011, 3 (5), 461-466.
87. Subramanian, M.; Manjunath, R.; Kilara, N.; Mohan Rao, K.N. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature. J. Cancer Res. Ther., 2010, 6 (3), 344-346.
88. Ram, R.; Ben-Bassat, I.; Shpilberg, O.; Polliack, A.; Raanani, P. The late adverse events of rituximab therapy--rare but there! Leuk. Lymphoma, 2009, 50 (7), 1083-1095.
89. Berger, J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf., 2010, 33 (11), 969-983.
90. Lysandropoulos, A.P.; Du Pasquier, R.A. Demyelination as a complication of new immunomodulatory treatments. Curr. Opin. Neurol., 2010, 23 (3), 226-233.
91. Chakravarty, E.F.; Murray, E.R.; Kelman, A.; Farmer, P. Pregnancy outcomes after maternal exposure to rituximab. Blood, 2011, 117 (5), 1499-1506.
92. Evans, J.T.; Shepard, M.M.; Oates, J.C.; Self, S.E.; Reuben, A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J. Clin. Gastroenterol., 2008, 42 (7), 862-863.
93. Barth, E.; Clawson, J. A Case of Autoimmune Hepatitis Treated with Rituximab. Case Rep. Gastroenterol., 2010, 4 (3), 502-509.
94. Czaja, A.J.; Donaldson, P.T. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol. Rev., 2000, 174, 250-259.
95. Najafian, N.; Sayegh, M.H. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin. Investig. Drugs, 2000, 9 (9), 2147-2157.
96. Czaja, A.J.; Doherty, D.G.; Donaldson, P.T. Genetic bases of autoimmune hepatitis. Dig. Dis. Sci., 2002, 47 (10), 2139-2150.
97. Donaldson, P.T.; Czaja, A.J. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin. Liver Dis., 2002, 6 (3), 707-725.
98. Czaja, A.J. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin. Gastroenterol. Hepatol., 2008, 6 (4), 379-388.
99. Gizinski, A.M.; Fox, D.A.; Sarkar, S. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets. Best Pract. Res. Clin. Rheumatol., 2010, 24 (4), 463-477.
100. Schwartz, J.C.; Zhang, X.; Fedorov, A.A.; Nathenson, S.G.; Almo, S.C. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature, 2001, 410 (6828), 604-608.
101. Linsley, P.S.; Nadler, S.G. The clinical utility of inhibiting CD28-mediated costimulation. Immunol. Rev., 2009, 229 (1), 307-321.
102. Hodi, F.S. Cytotoxic T-lymphocyte-associated antigen-4. Clin. Cancer Res., 2007, 13 (18 Pt 1), 5238-5242.
103. Scalapino, K.J.; Daikh, D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol. Rev., 2008, 223, 143-155.
104. Chikuma, S.; Bluestone, J.A. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res., 2003, 28 (3), 241-253.
105. Alegre, M.L.; Fallarino, F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr. Pharm. Des., 2006, 12 (2), 149-160.
106. Boden, E.; Tang, Q.; Bour-Jordan, H.; Bluestone, J.A. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found. Symp., 2003, 252, 55-63; discussion 63-56, 106-114.
107. Holmberg, D.; Cilio, C.M.; Lundholm, M.; Motta, V. CTLA-4 (CD152) and its involvement in autoimmune disease. Autoimmunity, 2005, 38 (3), 225-233.
108. Gough, S.C.; Walker, L.S.; Sansom, D.M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev., 2005, 204, 102-115.
109. Agarwal, K.; Czaja, A.J.; Jones, D.E.; Donaldson, P.T. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology, 2000, 31 (1), 49-53.
110. Djilali-Saiah, I.; Ouellette, P.; Caillat-Zucman, S.; Debray, D.; Kohn, J.I.; Alvarez, F. CTLA-4/CD 28 region polymorphisms in children from families with autoimmune hepatitis. Hum. Immunol., 2001, 62 (12), 1356-1362.
111. Fan, L.Y.; Tu, X.Q.; Cheng, Q.B.; Zhu, Y.; Feltens, R.; Pfeiffer, T.; Zhong, R.Q. Cytotoxic T lymphocyte associated antigen-4 gene polymorphisms confer susceptibility to primary biliary cirrhosis and autoimmune hepatitis in Chinese population. World J. Gastroenterol., 2004, 10 (20), 3056-3059.
112. Agarwal, K.; Jones, D.E.; Daly, A.K.; James, O.F.; Vaidya, B.; Pearce, S.; Bassendine, M.F. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol., 2000, 32 (4), 538-541.
113. Juran, B.D.; Atkinson, E.J.; Schlicht, E.M.; Fridley, B.L.; Petersen, G.M.; Lazaridis, K.N. Interacting alleles of the coinhibitory immunoreceptor genes cytotoxic T-lymphocyte antigen 4 and programmed cell-death 1 influence risk and features of primary biliary cirrhosis. Hepatology, 2008, 47 (2), 563-570.
114. Juran, B.D.; Atkinson, E.J.; Schlicht, E.M.; Fridley, B.L.; Lazaridis, K.N. Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene. Gastroenterology, 2008, 135 (4), 1200-1206.
115. Joshita, S.; Umemura, T.; Yoshizawa, K.; Katsuyama, Y.; Tanaka, E.; Nakamura, M.; Ishibashi, H.; Ota, M. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J. Hepatol., 2010, 53 (3), 537-541.
116. Juran, B.D.; Atkinson, E.J.; Larson, J.J.; Schlicht, E.M.; Liu, X.; Heathcote, E.J.; Hirschfield, G.M.; Siminovitch, K.A.; Lazaridis, K.N. Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology, 2010, 52 (1), 223-229.
117. Donaldson, P.; Veeramani, S.; Baragiotta, A.; Floreani, A.; Venturi, C.; Pearce, S.; Wilson, V.; Jones, D.; James, O.; Taylor, J.; Newton, J.; Bassendine, M. Cytotoxic T-lymphocyte-associated antigen-4 single nucleotide polymorphisms and haplotypes in primary biliary cirrhosis. Clin. Gastroenterol. Hepatol., 2007, 5 (6), 755-760.
118. Bittencourt, P.L.; Palacios, S.A.; Cancado, E.L.; Porta, G.; Carrilho, F.J.; Laudanna, A.A.; Kalil, J.; Goldberg, A.C. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am. J. Gastroenterol., 2003, 98 (7), 1616-1620.
119. Hirschfield, G.M.; Invernizzi, P. Progress in the genetics of primary biliary cirrhosis. Semin. Liver Dis., 2011, 31 (2), 147-156.
120. Sansom, D.M.; Walker, L.S. The role of CD28 and cytotoxic Tlymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev., 2006, 212, 131-148.
121. Henson, S.M.; Macaulay, R.; Kiani-Alikhan, S.; Akbar, A.N. The use of the inhibitory receptors for modulating the immune responses. Curr. Pharm. Des., 2008, 14 (26), 2643-2650.
122. Rudd, C.E.; Taylor, A.; Schneider, H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev., 2009, 229 (1), 12-26.
123. Poirier, N.; Blancho, G.; Vanhove, B. A more selective costimulatory blockade of the CD28-B7 pathway. Transpl. Int., 2011, 24 (1), 2-11.
124. Viglietta, V.; Khoury, S.J. Modulating co-stimulation. Neurotherapeutics, 2007, 4 (4), 666-675.
125. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.; MacRae, S.; Willman, A.; Padera, R.; Jaklitsch, M.T.; Shankar, S.; Chen, T.C.; Korman, A.; Allison, J.P.; Dranoff, G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U.S.A., 2003, 100 (8), 4712-4717.
126. Ribas, A.; Camacho, L.H.; Lopez-Berestein, G.; Pavlov, D.; Bulanhagui, C.A.; Millham, R.; Comin-Anduix, B.; Reuben, J.M.; Seja, E.; Parker, C.A.; Sharma, A.; Glaspy, J.A.; Gomez-Navarro, J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol., 2005, 23 (35), 8968-8977.
127. Camacho, L.H.; Antonia, S.; Sosman, J.; Kirkwood, J.M.; Gajewski, T.F.; Redman, B.; Pavlov, D.; Bulanhagui, C.; Bozon, V.A.; Gomez-Navarro, J.; Ribas, A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol., 2009, 27 (7), 1075-1081.
128. Ascierto, P.A.; Marincola, F.M.; Ribas, A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J. Transl. Med., 2011, 9, 196.
129. Goldzweig, O.; Hashkes, P.J. Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy. Drug Des. Devel. Ther., 2011, 5, 61-70.
130. Korhonen, R.; Moilanen, E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol., 2009, 104 (4), 276-284.
131. Ben-Shoshan, M. CTLA-4Ig: uses and future directions. Recent Pat. Inflamm. Allergy Drug Discov., 2009, 3 (2), 132-142.
132. Maxwell, L.; Singh, J.A. Abatacept for rheumatoid arthritis. Cochrane Database Syst. Rev., 2009, (4), CD007277.
133. Sakthivel, P. Bench to bedside of CTLA-4: a novel immunotherapeutic agent for inflammatory disorders. Recent Pat. Inflamm. Allergy Drug Discov., 2009, 3 (2), 84-95.
134. Guinan, E.C.; Boussiotis, V.A.; Neuberg, D.; Brennan, L.L.; Hirano, N.; Nadler, L.M.; Gribben, J.G. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med., 1999, 340 (22), 1704-1714.
135. Viglietta, V.; Bourcier, K.; Buckle, G.J.; Healy, B.; Weiner, H.L.; Hafler, D.A.; Egorova, S.; Guttmann, C.R.; Rusche, J.R.; Khoury, S.J. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology, 2008, 71 (12), 917-924.
136. Vermeiren, J.; Ceuppens, J.L.; Haegel-Kronenberger, H.; De Boer, M.; Boon, L.; Van Gool, S.W. Blocking B7 and CD40 costimulatory molecules decreases antiviral T cell activity. Clin. Exp. Immunol., 2004, 135 (2), 253-258.
137. Pham, T.; Claudepierre, P.; Constantin, A.; Fautrel, B.; Gossec, L.; Gottenberg, J.E.; Goupille, P.; Hachulla, E.; Masson, C.; Morel, J.; Saraux, A.; Schaeverbeke, T.; Wendling, D.; Mariette, X.; Sibilia, J. Abatacept therapy and safety management. Joint Bone Spine, 2009, 76 (Suppl 1), S3-S55.
138. Cowling, D.C.; Mackay, I.R.; Taft, L.I. Lupoid hepatitis. Lancet, 1956, 271 (6957), 1323-1326.
139. Mackay, I.R.; Taft, L.I.; Cowling, D.C. Lupoid hepatitis and the hepatic lesions of systemic lupus erythematosus. Lancet, 1959, 1 (7063), 65-69.
140. Alvarez, F.; Berg, P.A.; Bianchi, F.B.; Bianchi, L.; Burroughs, A.K.; Cancado, E.L.; Chapman, R.W.; Cooksley, W.G.; Czaja, A.J.; Desmet, V.J.; Donaldson, P.T.; Eddleston, A.L.; Fainboim, L.; Heathcote, J.; Homberg, J.C.; Hoofnagle, J.H.; Kakumu, S.; Krawitt, E.L.; Mackay, I.R.; MacSween, R.N.; Maddrey, W.C.; Manns, M.P.; McFarlane, I.G.; Meyer zum Buschenfelde, K.H.; Zeniya, M.; et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol., 1999, 31 (5), 929-938.
141. Czaja, A.J. The role of autoantibodies as diagnostic markers of autoimmune hepatitis. Expert Rev. Clin. Immunol., 2006, 2 (1), 33-48.
142. Czaja, A.J. Autoimmune hepatitis. Part B: diagnosis. Expert Rev. Gastroenterol. Hepatol., 2007, 1 (1), 129-143.
143. Hennes, E.M.; Zeniya, M.; Czaja, A.J.; Pares, A.; Dalekos, G.N.; Krawitt, E.L.; Bittencourt, P.L.; Porta, G.; Boberg, K.M.; Hofer, H.; Bianchi, F.B.; Shibata, M.; Schramm, C.; Eisenmann de Torres, B.; Galle, P.R.; McFarlane, I.; Dienes, H.P.; Lohse, A.W. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48 (1), 169-176.
144. Czaja, A.J. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J. Hepatol., 1999, 30 (3), 394-401.
145. Luth, S.; Herkel, J.; Kanzler, S.; Frenzel, C.; Galle, P.R.; Dienes, H.P.; Schramm, C.; Lohse, A.W. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J. Clin. Gastroenterol., 2008, 42 (8), 926-930.
146. Czaja, A.J. Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria. Gastroenterology, 2011, 140 (5), 1472-1480.
147. Longhi, M.S.; Ma, Y.; Bogdanos, D.P.; Cheeseman, P.; Mieli-Vergani, G.; Vergani, D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J. Hepatol., 2004, 41 (1), 31-37.
148. Longhi, M.S.; Ma, Y.; Mitry, R.R.; Bogdanos, D.P.; Heneghan, M.; Cheeseman, P.; Mieli-Vergani, G.; Vergani, D. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J. Autoimmun., 2005, 25 (1), 63-71.
149. Longhi, M.S.; Hussain, M.J.; Mitry, R.R.; Arora, S.K.; Mieli-Vergani, G.; Vergani, D.; Ma, Y. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J. Immunol., 2006, 176 (7), 4484-4491.
150. Longhi, M.S.; Meda, F.; Wang, P.; Samyn, M.; Mieli-Vergani, G.; Vergani, D.; Ma, Y. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology, 2008, 47 (2), 581-591.
151. Shevach, E.M.; McHugh, R.S.; Piccirillo, C.A.; Thornton, A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev., 2001, 182, 58-67.
152. Gavin, M.; Rudensky, A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr. Opin. Immunol., 2003, 15 (6), 690-696.
153. Thompson, C.; Powrie, F. Regulatory T cells. Curr. Opin. Pharmacol., 2004, 4 (4), 408-414.
154. Peterson, R.A. Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression. Toxicol. Pathol., 2012, 40 (2), 186-204.
155. Shimizu, J.; Yamazaki, S.; Takahashi, T.; Ishida, Y.; Sakaguchi, S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol., 2002, 3 (2), 135-142.
156. Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol., 2005, 6 (4), 345-352.
157. Yamaguchi, T.; Sakaguchi, S. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol., 2006, 16 (2), 115-123.
158. Su, H.; Longhi, M.S.; Wang, P.; Vergani, D.; Ma, Y. Human CD4+CD25(high)CD127 (low/neg) regulatory T cells. Methods Mol. Biol., 2012, 806, 287-299.
159. Wu, L.; Van Kaer, L. Natural killer T cells in health and disease. Front. Biosci. (Schol. Ed.), 2011, 3, 236-251.
160. Subleski, J.J.; Jiang, Q.; Weiss, J.M.; Wiltrout, R.H. The split personality of NKT cells in malignancy, autoimmune and allergic disorders. Immunotherapy, 2011, 3 (10), 1167-1184.
161. Nowak, M.; Stein-Streilein, J. Invariant NKT cells and tolerance. Int. Rev. Immunol., 2007, 26 (1-2), 95-119.
162. Van Kaer, L.; Parekh, V.V.; Wu, L. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy, 2011, 3 (1), 59-75.
163. Novak, J.; Lehuen, A. Mechanism of regulation of autoimmunity by iNKT cells. Cytokine, 2011, 53 (3), 263-270.
164. Zeissig, S.; Blumberg, R.S. Primary immunodeficiency associated with defects in CD1 and CD1-restricted T cells. Ann. N. Y. Acad. Sci., 2012, 1250 (1), 14-24.
165. Yang, J.Q.; Kim, P.J.; Singh, R.R. Brief treatment with iNKT cell ligand alpha-galactosylceramide confers a long-term protection against lupus. J. Clin. Immunol., 2012, 32 (1), 106-113.
166. Yoshiga, Y.; Goto, D.; Segawa, S.; Horikoshi, M.; Hayashi, T.; Matsumoto, I.; Ito, S.; Taniguchi, M.; Sumida, T. Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin. Exp. Immunol., 2011, 164 (2), 236-247.
167. Maurer, M.F.; Garrigues, U.; Jaspers, S.R.; Meengs, B.; Rixon, M.W.; Stevens, B.L.; Lewis, K.B.; Julien, S.H.; Bukowski, T.R.; Wolf, A.C.; Hamacher, N.B.; Snavely, M.; Dillon, S.R. Generation and characterization of human anti-human IL-21 neutralizing monoclonal antibodies. MAbs., 2012, 4 (1), 69-83.
168. Oh, S.J.; Chung, D.H. Invariant NKT cells producing IL-4 or IL-10, but not IFN-gamma, inhibit the Th1 response in experimental autoimmune encephalomyelitis, whereas none of these cells inhibits the Th17 response. J. Immunol., 2011, 186 (12), 6815-6821.
169. Walker, K.M.; Rytelewski, M.; Mazzuca, D.M.; Meilleur, S.A.; Mannik, L.A.; Yue, D.; Brintnell, W.C.; Welch, I.; Cairns, E.; Haeryfar, S.M. Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist. Immunol. Cell Biol., 2011, doi: 10.1038/icb.2011.78. [Epub ahead of print]
170. Cho, Y.N.; Kee, S.J.; Lee, S.J.; Seo, S.R.; Kim, T.J.; Lee, S.S.; Kim, M.S.; Lee, W.W.; Yoo, D.H.; Kim, N.; Park, Y.W. Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. Rheumatology (Oxford), 2011, 50 (6), 1054-1063.
171. Lee, I.F.; van den Elzen, P.; Tan, R.; Priatel, J.J. NKT cells are required for complete Freund's adjuvant-mediated protection from autoimmune diabetes. J. Immunol., 2011, 187 (6), 2898-2904.
172. Gomez-Diaz, R.A.; Aguilar, M.V.; Meguro, E.N.; Marquez, R.H.; Magana, E.G.; Martinez-Garcia, M.C.; Rodarte, N.W.; Aguilar-Salinas, C.A.; Canche-Pool, E.; Ortiz-Navarrete, V. The role of natural killer T (NKT) cells in the pathogenesis of type 1 diabetes. Curr. Diabetes Rev., 2011, 7 (4), 278-283.
173. Kadri, N.; Korpos, E.; Gupta, S.; Briet, C.; Lofbom, L.; Yagita, H.; Lehuen, A.; Boitard, C.; Holmberg, D.; Sorokin, L.; Cardell, S.L. CD4+ Type II NKT Cells Mediate ICOS and Programmed Death-1-Dependent Regulation of Type 1 Diabetes. J. Immunol., 2012, 188 (7), 3138-3149.
174. Cantorna, M.T.; Zhao, J.; Yang, L. Vitamin D, invariant natural killer T-cells and experimental autoimmune disease. Proc. Nutr. Soc., 2012, 71 (1), 62-66.
175. Dennert, G.; Aswad, F. The role of NKT cells in animal models of autoimmune hepatitis. Crit. Rev. Immunol., 2006, 26 (5), 453-473.
176. Kawamura, H.; Aswad, F.; Minagawa, M.; Govindarajan, S.; Dennert, G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J. Immunol., 2006, 176 (4), 2152-2160.
177. Santodomingo-Garzon, T.; Swain, M.G. Role of NKT cells in autoimmune liver disease. Autoimmun. Rev., 2011, 10 (12), 793-800.
178. Tupin, E.; Kronenberg, M. Activation of natural killer T cells by glycolipids. Methods Enzymol., 2006, 417, 185-201.
179. Lalazar, G.; Preston, S.; Zigmond, E.; Ben Yaacov, A.; Ilan, Y. Glycolipids as immune modulatory tools. Mini Rev. Med. Chem., 2006, 6 (11), 1249-1253.
180. Berzins, S.P.; Smyth, M.J.; Baxter, A.G. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol., 2011, 11 (2), 131-142.
181. Agarwal, K.; Czaja, A.J.; Donaldson, P.T. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens, 2007, 69 (3), 227-235.
182. Cookson, S.; Constantini, P.K.; Clare, M.; Underhill, J.A.; Bernal, W.; Czaja, A.J.; Donaldson, P.T. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology, 1999, 30 (4), 851-856.
183. Czaja, A.J.; Cookson, S.; Constantini, P.K.; Clare, M.; Underhill, J.A.; Donaldson, P.T. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology, 1999, 117 (3), 645-652.
184. Fan, L.Y.; Tu, X.Q.; Zhu, Y.; Pfeiffer, T.; Feltens, R.; Stoecker, W.; Zhong, R.Q. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J. Gastroenterol., 2005, 11 (18), 2768-2772.
185. Fan, L.; Tu, X.; Zhu, Y.; Zhou, L.; Pfeiffer, T.; Feltens, R.; Stoecker, W.; Zhong, R. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J. Gastroenterol. Hepatol., 2005, 20 (2), 249-255.
186. Hiraide, A.; Imazeki, F.; Yokosuka, O.; Kanda, T.; Kojima, H.; Fukai, K.; Suzuki, Y.; Hata, A.; Saisho, H. Fas polymorphisms influence susceptibility to autoimmune hepatitis. Am. J. Gastroenterol., 2005, 100 (6), 1322-1329.
187. Staatz, C.E.; Goodman, L.K.; Tett, S.E. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin. Pharmacokinet., 2010, 49 (3), 141-175.
188. Utecht, K.N.; Hiles, J.J.; Kolesar, J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am. J. Health Syst. Pharm., 2006, 63 (23), 2340-2348.
189. Yokosawa, S.; Yoshizawa, K.; Ota, M.; Katsuyama, Y.; Kawa, S.; Ichijo, T.; Umemura, T.; Tanaka, E.; Kiyosawa, K. A genomewide DNA microsatellite association study of Japanese patients with autoimmune hepatitis type 1. Hepatology, 2007, 45 (2), 384-390.
190. Davidson, B.L. Hepatic diseases--hitting the target with inhibitory RNAs. N. Engl. J. Med., 2003, 349 (24), 2357-2359.
191. Hannon, G.J. RNA interference. Nature, 2002, 418 (6894), 244-251.
192. Hannon, G.J.; Rossi, J.J. Unlocking the potential of the human genome with RNA interference. Nature, 2004, 431 (7006), 371-378.
193. McCafferty AP, N.H., Pandey K, Huang Z, Salazar FH, Xu H, Wieland SF, Marion PL, Kay MA. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol., 2003, 21, 639-644.
194. Song, E.; Lee, S.K.; Wang, J.; Ince, N.; Ouyang, N.; Min, J.; Chen, J.; Shankar, P.; Lieberman, J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med., 2003, 9 (3), 347-351.
195. Zhang, Y.; Zhang, J.W.; Lv, G.Y.; Xie, S.L.; Wang, G.Y. Effects of STAT3 Gene Silencing and Rapamycin on Apoptosis in Hepatocarcinoma Cells. Int. J. Med. Sci., 2012, 9 (3), 216-224.
196. Kerr, T.A.; Davidson, N.O. Therapeutic RNA manipulation in liver disease. Hepatology, 2010, 51 (3), 1055-1061.
197. Duffy, M.M.; Ritter, T.; Ceredig, R.; Griffin, M.D. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res. Ther., 2011, 2 (4), 34.
198. Kuo, T.K.; Hung, S.P.; Chuang, C.H.; Chen, C.T.; Shih, Y.R.; Fang, S.C.; Yang, V.W.; Lee, O.K. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology, 2008, 134 (7), 2111-2121, 2121 e2111-2113.
199. Szodoray, P.; Varoczy, L.; Papp, G.; Barath, S.; Nakken, B.; Szegedi, G.; Zeher, M. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand. J. Rheumatol., 2012, 41 (2), 110-115.
200. Manns, M.P.; Czaja, A.J.; Gorham, J.D.; Krawitt, E.L.; Mieli-Vergani, G.; Vergani, D.; Vierling, J.M. Practice Guidelines of the American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51 (6), 2193-2213.
201. Manns, M.P.; Woynarowski, M.; Kreisel, W.; Lurie, Y.; Rust, C.; Zuckerman, E.; Bahr, M.J.; Gunther, R.; Hultcrantz, R.W.; Spengler, U.; Lohse, A.W.; Szalay, F.; Farkkila, M.; Prols, M.; Strassburg, C.P. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology, 2010, 139 (4), 1198-1206.
202. Czaja, A.J. Advances in the current treatment of autoimmune hepatitis. Dig. Dis. Sci., 2012, Epub ahead of print 2012 April 3; DOI:10.1007/s10620-012-2151-2.
203. Czaja, A.J. Autoimmune hepatitis: focusing on treatments other than steroids. Can. J. Gastroenterol., 2012, in press.
204. Czaja, A.J. Treatment strategies in autoimmune hepatitis. Clin. Liver Dis., 2002, 6 (3), 799-824.
205. Czaja, A.J.; Carpenter, H.A. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J. Clin. Gastroenterol., 2005, 39 (9), 819-825.
206. Czaja, A.J. Difficult treatment decisions in autoimmune hepatitis. World J. Gastroenterol., 2010, 16 (8), 934-947.
207. Cross, T.J.; Antoniades, C.G.; Muiesan, P.; Al-Chalabi, T.; Aluvihare, V.; Agarwal, K.; Portmann, B.C.; Rela, M.; Heaton, N.D.; O'Grady, J.G.; Heneghan, M.A. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl., 2007, 13 (10), 1382-1388.
208. Vogel, A.; Heinrich, E.; Bahr, M.J.; Rifai, K.; Flemming, P.; Melter, M.; Klempnauer, J.; Nashan, B.; Manns, M.P.; Strassburg, C.P. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin. Transplant., 2004, 18 (1), 62-69.
209. Sanchez-Urdazpal, L.; Czaja, A.J.; van Hoek, B.; Krom, R.A.; Wiesner, R.H. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology, 1992, 15 (2), 215-221.
210. Manns, M.P. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology, 2011, 140 (7), 1874-1876.